SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) today announced that it has filed a patent infringement suit relating to BGI’s “CoolMPS” sequencing products. The complaint was filed against BGI Genomics Co., Ltd., BGI Americas Corp., MGI Tech Co., Ltd., MGI Americas, Inc. and Complete Genomics Inc. in the United States District Court for the Northern District... Read more
SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) today announced that it has filed two additional patent infringement suits relating to BGI’s sequencing products, including the DNBSeq-400 (also known as MGISeq-2000), DNBSeq-T7, and related chemistry reagents. The first complaint was filed against MGI Tech Co., Ltd. and Latvia MGI Tech SIA in the High Court of Justice,... Read more
SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) today announced that it has filed three additional patent infringement suits relating to BGI’s sequencing products, including the BGISeq-500, MGISeq-2000, and related chemistry reagents. The first complaint was filed against Complete Genomics, Inc. and other BGI entities in the United States District Court for the Northern District of California... Read more
Collaboration assures BGI’s and NRGene’s commitment to provide the most advanced technological breeding tools the Asian market June 6, 2019, Ness Ziona, Israel and Shenzhen, China BGI, the world’s largest omics organization, announced today that it will be offering NRGene’s technology as part of its broad genomics analysis services in agriculture research. BGI supports genomic... Read more
SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) today announced that it has filed another patent infringement suit against one of BGI Group’s subsidiaries, BGI Europe A/S. Illumina filed suit in the Maritime & Commercial High Court of Denmark. “As we have previously stated, Illumina will continue to vigorously protect our patented technology and file patent suits... Read more
SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) today announced that it has filed a patent infringement suit against BGI Group’s subsidiary, Latvia MGI Tech SIA, in the Düsseldorf Regional Court in Germany. The complaint alleges that BGI’s sequencing products, including the BGISeq-500, MGISeq-2000, and related chemistry reagents, infringe EP 1 530 578 B1. This patent covers... Read more
MENLO PARK, California and SHENZHEN, China, Jan. 25, 2018 (GLOBE NEWSWIRE) — BGI, one of the world’s largest genomics organizations, and Pacific Biosciences of California, Inc. (Nasdaq: PACB), the leader in long-read sequencing, today announced an agreement by BGI Genomics to purchase an additional 10 Sequel® Systems. This will significantly expand the capacity for Single Molecule, Real-Time... Read more
–MGI’s BGISEQ-500RS Genetic Sequencer, Forthcoming MGISEQ Genetic Sequencers Compatible with 10x Genomics Solutions– PLEASANTON, CA. and SHENZHEN, CHINA —January 8, 2018—10x Genomics, Inc. and MGI, a subsidiary of BGI, today announced that the BGISEQ-500RS genetic sequencer has met the rigorous standards of the new 10x Genomics Compatible Program. MGI will also ensure that the MGISEQ... Read more